United Kingdom (UK)
Recombinant monoclonal antibody to Digoxin. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 26 / 10.
Alternative Name(s) of Target: Digitalis
Immunogen: Spleen cells from A/J mice immunized with digoxin coupled to human serum albumin (Dig-HSA).
Specificity: The antibody binds digoxin with an affinity (Kd) of 9 nM.
Application Notes: The antibody is specific for digoxin, a cardiac glycoside derived from the foxglove plant. Digoxin is administered for the therapeutic treatment of heart conditions such as atrial fibrillation, atrial flutter and heart failure, an acts by inhibiting the Na+/K+ ATPase. However, the drug has a very narrow therapeutic index and can cause toxic side effects. The Fab fragment prepared from 26-10 that neutralises the activity of digoxin and can be used as an antidote in case of overdose of digitalis. Anti-digoxin monoclonal antibodies can also be used to measure serum levels of the drug as a guide to therapy, and are useful in the investigation of the kinetics of interaction between antibody and antigen.
Antibody first published in:
Mudgett-Hunter M, Anderson W, Haber E, Margolies MN. Binding and structural diversity among high-affinity monoclonal anti-digoxin antibodies. Mol Immunol. 1985 Apr;22(4):477-88. PMID:4033667
Note on publication:
Describes the generation of high-affinity monoclonal anti-digoxin antibodies using the hybridoma technology. The antibodies can be useful for the study of structure-function relationships between antibody binding site and antigenic determinants.